Sarepta Therapeutics: Peers

The FY2025 (Dec) proxy of Sarepta Therapeutics names 17 peer companies for pay. Among Sarepta Therapeutics and these peers, CEO pay was 11th highest of 13 and total shareholder return was the lowest of 13.

11th highest of 13in Sarepta Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$6.1M$33.2M

13th highest of 13in Sarepta Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$13$321

Pay peer group, FY2025 (Dec) proxy

Exelixis
Incyte
PTC Therapeutics
Halozyme Therapeutics
Biomarin Pharmaceutical
United Therapeutics
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Ultragenyx Pharmaceutical
Alkermes plc.
Neurocrine Biosciences
Repligen
Acadia PharmaceuticalsNot disclosedNot disclosed
ArgenxNot disclosedNot disclosed
Blueprint MedicinesNot disclosedNot disclosed
Jazz PharmaceuticalsNot disclosedNot disclosed
Vertex PharmaceuticalsNot disclosedNot disclosed
17 companies

Changes by year

FY2025 (Dec) proxy

  • AddedArgenxpay peer group
  • AddedVertex Pharmaceuticalspay peer group
  • RemovedHorizon Therapeuticspay peer group

FY2024 (Dec) proxy

  • RemovedAmicus Therapeuticspay peer groupAmicus Therapeutics and Horizon Therapeutics, which were members of our 2023 peer group, were not included in the 2024 Peer Group as they no longer met all of the relevant criteria
  • RemovedHorizon Therapeuticspay peer groupAmicus Therapeutics and Horizon Therapeutics, which were members of our 2023 peer group, were not included in the 2024 Peer Group as they no longer met all of the relevant criteria

FY2023 (Dec) proxy

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.